Search company, investor...
Search

Predict your next investment

Venture Capital
renegadepartners.com

See what CB Insights has to offer

Investments

15

Portfolio Exits

1

Funds

2

About Renegade Partners

Renegade Partners is a venture capital firm focused on investing in Series B rounds.

Renegade Partners Headquarters Location

San Francisco, California,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Renegade Partners News

Auxilius Raises $10 Million To Streamline Clinical Trial Financial Management

Jun 30, 2022

Auxilius recently announced that it raised $10 million in funding. These are the details. Auxilius, a company that simplifies and streamlines clinical trial financial management for biotech companies, announced it has raised $10 million in Series A funding. This funding round was led by Renegade Partners with participation from previous investors Bain Capital Ventures and XYZ Venture Capital, as well as a number of prominent angel investors, including Andy Palmer (Koa Labs), Chase Gilbert (Built Technologies), and Sam Whitaker (Greenphire). Roseanne Wincek from Renegade Partners is joining the board. Over the past decade, 2 distinct trends shaped drug development. For example, a notable shift in where innovation takes place – with over 80% of registered clinical trials now sponsored by emerging biopharma companies, up from 55% in 2009. And second, clinical operations are increasingly outsourced to external vendors, including Clinical Research Organizations (CROs) and a growing set of functional and decentralized service providers. The result is an evolving – and growing – shadow industry that emerging biopharma companies are ill-equipped to manage operationally. As biotech companies progress from lab to clinic to IPO, drug development is no longer just about science. And nearly one-quarter of Phase 3 trials fail due to lack of funding – not because of the safety or efficacy of the treatment. For clinical trial sponsors managing milestone to milestone, operational rigor and spend management are essential to extend the company’s runway and help clinical teams achieve clinical outcomes. The Auxilius SaaS platform unifies disparate clinical, contractual, and financial data to empower companies to streamline core FP&A and accounting workflows, hold outsourced vendors accountable through change and puts processes in place that support audit, compliance, and reporting requirements. And the platform was built to serve the needs and pace of growth at emerging, scaling, and mature biotech companies – providing the same financial and operational rigor that would exist at a top 10 pharma company for less than the cost of a full-time employee. Since launching late last year, Auxilius has been in pilot with clinical trial sponsors managing 15 pre-clinical through Phase 3 programs, 45 distinct vendors, and nearly $100 million in trial spend. And the company expects the solution to be deployed at 25 clients by end-of-year. KEY QUOTES: “We’ve all learned how critical biotechs are for the well-being of our communities. And yet, they have been largely tech-forgotten, lacking basic financial tooling to operate at scale. Auxilius powers essential financial processes and workflows — enabling clinical organizations to focus on life-saving science.” — Ross Fubini, founder and managing partner of XYZ Venture Capital “Auxilius empowers financial leaders at biopharma companies to make sound business decisions so they can support the important work of their colleagues in clinical development. We provide a powerful toolset that makes it exponentially easier for companies to oversee all of the moving parts – contract terms, change orders, clinical milestones, and financial complexities – to keep trial budgets on track.” “It’s tempting to believe that clinical R&D is inherently unpredictable, and given what’s at stake, that costs don’t matter. The reality is that costs do matter and play an essential role in determining whether a therapy is ultimately successful. As we look ahead, we are committed to reducing financial risk and infusing financial intelligence at every step in the drug development life cycle. We fundamentally believe that combining financial rigor with cutting-edge science will ultimately make more life-saving therapies available, at affordable costs.” — Adam Weisman, co-founder and CEO of Auxilius “This industry is awash with clinical tools and industry agnostic FP&A software, but the bulk of clinical R&D spend has historically been managed manually in spreadsheets. Auxilius was purpose-built for companies like ours to manage clinical complexity, maintain alignment across clinical and financial stakeholders through change, and scale as our organization evolves.” — Adam Mostafa, CFO of X4 Pharma “The benefit of the Auxilius platform is immediately apparent to the biotech companies that now drive the majority of drug research and development. Auxilius could be the difference between bringing a cure for disease to market and seeing it languish in a lab.” —Roseanne Wincek, co-founder and managing director at Renegade Partners

Renegade Partners Investments

15 Investments

Renegade Partners has made 15 investments. Their latest investment was in Auxilius as part of their Series A on June 6, 2022.

CBI Logo

Renegade Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/16/2022

Series A

Auxilius

$10M

Yes

5

2/8/2022

Series C

Rewire

$25M

No

4

1/6/2022

Series B

Spekit

$45M

No

8

11/10/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

7/29/2021

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2022

2/8/2022

1/6/2022

11/10/2021

7/29/2021

Round

Series A

Series C

Series B

Series B

Series B - II

Company

Auxilius

Rewire

Spekit

Subscribe to see more

Subscribe to see more

Amount

$10M

$25M

$45M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

4

8

10

10

Renegade Partners Portfolio Exits

1 Portfolio Exit

Renegade Partners has 1 portfolio exit. Their latest portfolio exit was Rewire on August 16, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/16/2022

Acquired

$99M

13

Date

8/16/2022

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

13

Renegade Partners Fund History

2 Fund Histories

Renegade Partners has 2 funds, including Renegade Partners I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

7/7/2021

Renegade Partners I

$100M

2

Renegade Partners

10

Closing Date

7/7/2021

Fund

Renegade Partners I

Renegade Partners

Fund Type

Status

Amount

$100M

Sources

2

10

Renegade Partners Team

2 Team Members

Renegade Partners has 2 team members, including current Founder, Managing Director, Renata Quintini.

Name

Work History

Title

Status

Renata Quintini

Lux Capital, StartX, Felicis, Stanford Management Company, J.P. Morgan & Co., and Skadden, Arps, Slate, Meagher & Flom

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Renata Quintini

Subscribe to see more

Work History

Lux Capital, StartX, Felicis, Stanford Management Company, J.P. Morgan & Co., and Skadden, Arps, Slate, Meagher & Flom

Title

Founder, Managing Director

Subscribe to see more

Status

Current

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.